Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from NeOnc Technologies Holdings, Inc. ( (NTHI) ).
On November 7, 2025, NeOnc Technologies Holdings, Inc. announced an investor conference call scheduled for November 12, 2025, to present data updates from its ongoing Phase 1/2a NEO100-1 clinical trial and compassionate use program. The discussion will focus on MRI-based radiographic response data, progression-free survival, and overall survival trends for patients with recurrent high-grade malignant glioma, potentially impacting the company’s operations and industry positioning.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on developing and commercializing central nervous system therapeutics designed to overcome the blood-brain barrier. The company’s NEO™ drug development platform has produced novel drug candidates and delivery methods, with patent protections extending to 2038. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status.
Average Trading Volume: 78,094
Technical Sentiment Signal: Strong Buy
Current Market Cap: $193.9M
Find detailed analytics on NTHI stock on TipRanks’ Stock Analysis page.